Published Date: 13 Dec 2024
Top news in 2024 included the first CAR-T approval for CLL, triplet regimens, and more
Read Full NewsIn a new trial, patients with PD-L1 CPS ≥ 1 HNSCC were randomly assigned 1:1 to receive 20 mg/d lenvatinib orally plus pembrolizumab 200 mg intravenously or placebo orally once daily plus pembrolizumab 200 mg intravenously.
The agency also granted traditional approval to later-line nivolumab indications for certain adults with the disease.
1.
Cancer Vaccines' Emergence; More Focus on Side Effects; A Nudge for Exercise.
2.
Smart exercise planning could boost recovery for people with cancer
3.
Updates from the 2022 WHO classification of kidney epithelial tumors
4.
ALK-positive lung cancer trial results show unprecedented progression-free survival.
5.
After two years, a significant left nasal obstruction was finally diagnosed.
1.
Impact of Hormone Therapy Cessation on Tumor Growth: Case Study of Ki-67 Reduction
2.
Gut microbiota in curing cancer
3.
Revolutionizing Cancer Treatment with Mercaptopurine: A New Hope for Patients
4.
Revolutionizing Oncology: AI in Radiology, Machine Learning in Pathology, and Deep Learning for Cancer Detection
5.
Understanding Drug-Induced Cardiotoxicity: Mechanisms, Impact, and Future Directions
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part V
2.
Expert Group meeting with the management of EGFR mutation positive NSCLC - Part III
3.
An In-Depth Look At The Signs And Symptoms Of Lymphoma- Further Discussion
4.
Navigating the Complexities of Ph Negative ALL - Part I
5.
Understanding Early Relapse in B-cell ALL: Rates, Risks, and Common Sites
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation